Results 11 to 20 of about 3,690 (153)
Journal of Global Antimicrobial Resistance, 2023 : Here we report the in vivo development of cefiderocol resistance within 11 days after therapy initiation in a critically ill patient with bloodstream infection, infection of peri-anal fistula, and pneumonia caused by a VIM-2 harbouring, carbapenem ...
Luise Brakert +8 more
doaj +1 more source
Total and Unbound Pharmacokinetics of Cefiderocol in Critically Ill Patients
Pharmaceutics, 2022 Background: Cefiderocol is a siderophore cephalosporin antibiotic active against Gram-negative bacteria, including extended-spectrum beta-lactamase and carbapenemase-producing strains.
Noël Zahr +11 more
doaj +1 more source
Microbiology Spectrum, 2022 Cefiderocol has been approved in the United States and Europe but not in China. We aim to evaluate carbapenem-resistant Enterobacterales (CRE) susceptibility to cefiderocol to provide baseline data and investigate the resistance mechanism.
Qi Wang +16 more
doaj +1 more source
In vitro activity of cefiderocol against Gram-negative bacterial pathogens in Germany
Journal of Global Antimicrobial Resistance, 2022 : Objectives: Widespread antimicrobial resistance in Gram-negative bacteria (GNB), particularly carbapenem resistance, represents a major clinical challenge.
Philipp Thelen +5 more
doaj +1 more source
Therapeutic Advances in Urology, 2022 Cefiderocol is a unique siderophore cephalosporin antimicrobial agent that has shown promise in treating complicated urinary tract infections (cUTI). Urinary tract infections are commonly diagnosed infections with risk increasing with age and prevalence ...
Hongmei Wang, Brittany N. Palasik
doaj +1 more source
Microbiology Spectrum, 2023 In this study, we aimed to comparatively evaluate the in vitro activity of cefiderocol versus other antimicrobials against a well-characterized collection of metallo-beta-lactamase (MBL)-producing Gram-negative bacilli (MBL-GNB) isolates from hospitals ...
M. Delgado-Valverde +4 more
doaj +1 more source
Journal of Global Antimicrobial Resistance, 2021 : Objectives: The incidence of antimicrobial resistance in Europe is rising. Cefiderocol is approved in Europe for treatment of aerobic Gram-negative bacterial (GNB) infections in adults with limited treatment options. We report the in vitro activity of
Emilia Cercenado +5 more
doaj +1 more source
Journal of Global Antimicrobial Resistance, 2021 Objectives: The aim of this study was to investigate the clinical efficacy and safety of cefiderocol in the treatment of acute bacterial infections. Methods: The PubMed, Embase and Cochrane Library databases as well as the clinical trials registries of ...
Shun-Chung Hsueh +4 more
doaj +1 more source
Metallo-sideromycin as a dual functional complex for combating antimicrobial resistance
Nature Communications, 2023 The rapid emergence of antimicrobial resistance (AMR) pathogens highlights the urgent need to approach this global burden with alternative strategies. Cefiderocol (Fetroja®) is a clinically-used sideromycin, that is utilized for the treatment of severe ...
Chenyuan Wang +9 more
doaj +1 more source
Antibacterial spectrum of cefiderocol
Revista Española de Quimioterapia, 2022 Cefiderocol, a siderophore catechol cephalosporin, recently introduced in the market has been developed to enhance the in vitro activity of extended spectrum cephalosporins and to avoid resistance mechanisms affecting cephalosporins and carbapenems. The in vitro study of cefiderocol in the laboratory requires iron depleted media when MIC values are ...
Cordero, Desirée Gijón +3 more
openaire +2 more sources